Advertisement

Antiviral Activities of a Human Monoclonal Antibody against Human Cytomegalovirus

  • Takami Tomiyama
  • Yasuhiko Masuho
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 278)

Abstract

Human cytomegalovirus (CMV) causes infections ranging from subclinical illness to severe disease with significant morbidity and mortality in immunocompromised hosts such as recipients of organ or bone marrow transplants (1, 2), patients with acquired immunodeficiency syndrome (3), and newborn babies (4). The immune mechanisms which restrict human CMV infections are thought to involve cellular immune response more than humoral immune response. This is indicated by the facts that patients with deficiencies of cell-mediated immunity are at high risk of CMV disease and such patients develop severe CMV disease despite the presence of antibodies in their serum (5). Nevertheless, there is some evidence to suggest that humoral antibodies are effective in preventing serious consequences of CMV infection. Passive immunization with human immunoglobulin, especially with a high titer against CMV, has been shown to reduce the incidence of symptomatic CMV infection in transplant recipients (6, 7). Preexisting maternal antibodies also provide some protection against severe CMV infection in newborns (8). These findings suggest that a monoclonal antibody (MAb) of very high titer would provide a potent protective effect against this disease.

Keywords

Viral Spread Neutralization Activity Virus Neutralization Human MAbs Viral Plaque 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Dummer, J. S., White, L. T., Griffth, B. P., Hardesty, R. T., Bahnson, H. T., (1985) J. Infect. Dis 152, 1182–1191.PubMedCrossRefGoogle Scholar
  2. 2.
    Meyers, J. D. (1985) in The Herpesviruses, eds. Roizman, B. and Lopez, C. (Plenum, New York), Vol. 4, pp. 201–227.Google Scholar
  3. 3.
    Quinnan, G. V., Jr., Masur, H., Rook, A. H., Armstrong, G., Frederick, W. R., Epstein, J., Manischewitz, J. F., Macher, A. M., Jackson, L., Ames, J., Smith, H. A., Parker, M., Pearson, G. R., Parrillo, J., Mitchell, C. and Straus, S. (1984) DAMA 252, 72–77.Google Scholar
  4. 4.
    Saigal, S., Lunyk, O., Larke, B. and Charnesky, M. A. (1982) Am. J. Dis. Child. 136, 896–901.PubMedGoogle Scholar
  5. 5.
    Grundy, J. E., Super, M. and Griffiths, P. D. (1986) Lancet 1, 159–160.PubMedCrossRefGoogle Scholar
  6. 6.
    Condie, R. M. and O’Reilly, R. J. (1984) Am. J. Med 76 (suppl. 3A), 134–141.PubMedCrossRefGoogle Scholar
  7. 7.
    Snydman, D. R., Werner, B. G., Heinze-Lacey, B. and Bernardi, V. P. (1987) N. Engl. J. Med 317, 1049–1054.PubMedCrossRefGoogle Scholar
  8. 8.
    Stagno, S., Pass, R. F., Dworsky, M. E., Henderson, R. E., Moore, E. G., Walton, P. D. and Alford, C. A. (1982) N. Engl. J. Med 306, 945–949.PubMedCrossRefGoogle Scholar
  9. 9.
    Emanuel, D., Gold, J., Colacino, J., Lopez, C. and Hammerling, U. (1984) J. ImmunoL 133, 2202–2205.PubMedGoogle Scholar
  10. 10.
    Redmond, M. J., Leyritz-Wills, M., Winger, L. and Scraba, D. G. (1986) J. Virol. Methods 14, 9–24.PubMedCrossRefGoogle Scholar
  11. 11.
    Sutherland, S., Crawford, D. H., Wilson, S. A., Morgan, B., Azim, T. and Huehns, E. R. (1987) J. Med Virol. 22, 245–255.PubMedCrossRefGoogle Scholar
  12. 12.
    Matsumoto, Y., Sugano, T., Miyamoto, C. and Masuho, Y. (1986) Biochem. Biophys. Res. Commun. 137, 273–280.PubMedCrossRefGoogle Scholar
  13. 13.
    Tomiyama, T., Matsumoto, Y., Sugano, T., Fujinaga, S. and Masuho, Y. (in press) J. Immunol. Methods.Google Scholar
  14. 14.
    Masuho, Y., Matsumoto, Y., Sugano, T., Fujinaga, S.and Minamishima, Y. (1987) J. Gen. Virol. 68, 1457–1464.PubMedCrossRefGoogle Scholar
  15. 15.
    Murakami, H., Shimomura, T., Nakamura, T., Ohashi, H., Shinohara, K. and Omura, H. (1984) J. Agric. Chem. Soc. Jpn. 58, 575–583.Google Scholar
  16. 16.
    Masuho, Y., Matsumoto, T., Tomiyama, T., Sugano, T., and Ono, S. (in press) Int. J. Biol. Stand.Google Scholar
  17. 17.
    Tanaka, J., Ogura, T., Sato, H. and Hatano, M. (1987) Virology 161, 62–72.PubMedCrossRefGoogle Scholar
  18. 18.
    McKeating, J. A., Griffiths, P. D. and Grundy, J. E. (1987) J. Gen. ViroL 68, 785–792.PubMedCrossRefGoogle Scholar
  19. 19.
    Rasmussen, L., Mullenax, J., Nelson, R. and Merigan, T. C. (1985) J. Virol. 55, 274–280.PubMedGoogle Scholar
  20. 20.
    Lussenhop, N. O., Goertz, R., Webuke-Bunoti, M., Gehrz, R. and Kati, B. (1988) Virology 164, 362–372.PubMedCrossRefGoogle Scholar
  21. 21.
    Britt, W. J., Vugler, L. and Stephens, E. B. (1988) J. Virol. 62, 3309–3318.PubMedGoogle Scholar
  22. 22.
    Hooks, J. J., Burns, W., Hayashi, K., Geis, S. and Notkins, A. L. (1976) Infect. Immun. 14, 1172–1178.PubMedGoogle Scholar
  23. 23.
    Keller, P. M., Davison, A. J., Lowe, R. S., Riemen, M. W. and Ellis, R. W. (1987) Virology 157, 526–533.PubMedCrossRefGoogle Scholar
  24. 24.
    Cranage, M. P., Smith, G. L., Bell, S. E., Hart, H., Brown, C., Bankier, A. T., Tomlinson, P., Barrell, B. G. and Minson, T. C. (1988) J. ViroL 62, 1416–1422.PubMedGoogle Scholar
  25. 25.
    Rasmussen, L. E., Nelson, R. M., Kelsall, D. C. and Merigan, T. C. (1984) Proc. NatL Acad Sci. USA 81, 876–880.Google Scholar
  26. 26.
    Fuller, A. O., Santos, R. E. and Spear, P. G. (1989) J. ViroL 63, 3435–3443.PubMedGoogle Scholar
  27. 27.
    Forghani, B., Dupuis, K. W. and Schmidt, N. J. (1984) J. ViroL 52, 52–62.Google Scholar
  28. 28.
    Fujinaga, S., Sugano, T., Matsumoto, Y., Masuho, Y. and Mori, R. (1987) J. Infect. Dis. 155, 45–53.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1990

Authors and Affiliations

  • Takami Tomiyama
    • 1
  • Yasuhiko Masuho
    • 1
  1. 1.Teijin Institute for Biomedical ResearchHino City, Tokyo 191Japan

Personalised recommendations